focus -WSS

focus

author：comprehensive 2025-09-01 15:18:01 - browse：39

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： eGenesis tests gene

hotspot

focus

WSS

NIH launches clinical trials and new research office for long Covid

What to expect as Trump is arraigned on his Jan 6. indictment

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

5 important ways Henrietta Lacks changed medical science

NIH director takes cautious approach to Biden drug pricing priority

Wikipedia

focus

Wikipedia

Medical records are filled with copy

Mitch McConnell episode has important public health takeaway

Cancer drug shortages should be causing more outrage

eGenesis tests gene

Medical leaders decry Supreme Court decision on affirmative action

‘Oppenheimer’ and the risks of AI in health care

Drug repurposing or repositioning? The language matters

Parkinson’s finding may lead to tests and, someday, treatments

Novavax promises a turnaround & Lilly roils the obesity market

‘Oppenheimer’ and the risks of AI in health care

entertainment

EQRx, failed developer of low

EQRx, failed developer of low

Think you might have Covid

Copay coupons to count toward deductibles, after Biden court move

New safety details link Apellis eye drug to rare cases of blindness

Research misconduct: Proposed new rules face resistance

hotspot

focus

Wikipedia

leisure time